Corporate

Life Sciences

Experience

Wiggin and Dana counsels diverse clients with their collaborative research, discovery, development, licensing, manufacturing and marketing arrangements for products and technologies targeting a broad range of therapeutic and diagnostic areas. Wiggin and Dana also represents life sciences clients on mergers, acquisitions, and divestments of businesses, facilities, and product rights, both domestic and cross-border. Our strong and long-standing record of successfully negotiated agreements with biotechnology, pharmaceutical, medical device and diagnostics industry leaders has received national and international recognition.

Listed below are representative samples of corporate partnering transactions and mergers and acquisitions in which Wiggin and Dana has acted as counsel. Each transaction is described according to its status upon completion of the transaction.

For a list of Representative Corporate Partnering Transactions, please see below or click here to view a PDF.

For a list of Representative Mergers and Acquisitions, please see below or click here to view a PDF.

Highlighted Recent Life Sciences Corporate Partnering and Merger and Acquisition Transactions 

  • Affibody AB’s collaboration and license agreement with Alexion Pharmaceuticals, Inc. to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). ABY-039 has been specifically designed to combine Affibody’s proprietary protein therapeutics platforms to achieve a long half-life, which, along with its small size provides the potential for less frequent, convenient, at-home subcutaneous administration.  Under the terms of the agreement, Affibody is eligible to receive up to $650 million in upfront payments, and development and sales milestones, and tiered low double-digit royalties. Affibody retained the rights to lead clinical development of ABY-039 in an undisclosed indication and has the option to co-promote ABY-039 in the United States.
  • Represented Olink Proteomics Holding AB in the sale of Olink Proteomics to Summa Equity, a Swedish-based private equity firm that focuses on investments in companies that help solve global challenges. Olink Proteomics is a life science company that has developed a unique technology for human biomarker discovery. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide.
  • Swedish Orphan Biovitrum AB’s exclusive license and acquisition of global rights for emapalumab from Novimmune SA. Emapalumab is a late stage orphan drug candidate that addresses a high unmet medical need in primary haemophagocytic lymphohistiocytosis, a rare and life-threatening syndrome of extreme immune activation. Under the terms of the agreement, SOBI will make an upfront payment of 50 million Swiss francs and additional milestone payments of 400 million Swiss francs.
  • Aptar Pharma’s (part of AptarGroup, Inc.) collaboration with Propeller Health to launch a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The platform will span inhaled, injectable, nasal and dermal medicine delivery forms, and combine software and experiences with connected drug delivery devices. Aptar and Propeller will co-market the platform, with Propeller managing the digital services and Aptar managing the device development, manufacturing and supply chain.
  • BioInvent International AB’s collaboration and license agreement with Pfizer Inc. to undertake a research collaboration to discover and develop novel immuno-regulatory antibodies to treat cancer. BioInvent will apply its unbiased translational drug discovery platform (“F.I.R.S.T.”) to identify novel oncology targets and therapeutic antibodies targeting tumor-associated myeloid cells. BioInvent will receive approximately $10 million in early payments, including an upfront payment, early research funding and an equity investment. Assuming five antibodies are developed through to commercialization, BioInvent would be eligible for potential future development milestone payments of more than $0.5 billion through the term of the deal, as well as double digit royalties on sales of products that result from the collaboration.
  • Nuevolution A/S (publ)’s collaboration and license agreement with Almirall S.A. to undertake a research collaboration to develop and commercialize novel RORyt inhibitors for treatment of inflammatory skin diseases as well as Psoriatic Arthritis. The parties will collaborate to identify additional RORyt inhibitors. Almirall has an exclusive option to use the additional inhibitors in the dermatological field and with the optional use outside the field of collaboration for Nuevolution. Nuevolution will receive €11.2 million upfront and is eligible to receive up to € 172 million in development and regulatory milestone payments and up to EUR €270 million in tiered commercial sales milestones. Nuevolution would also be entitled to receive tiered royalties on future sales.
  • Represented Cormorant Pharmaceuticals AB in its stock purchase agreement in connection with the sale to Bristol-Myers Squibb Company (BMS) of all of Cormorant’s outstanding capital stock and in which BMS obtained full rights to Cormorant's lead antibody candidate, HuMax-IL8. HuMax-IL8 is a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) that represents a complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules. Payments by BMS to the Cormorant equity holders could reach a total of $520 million if all clinical and regulatory milestones are achieved.
  • Represented Probi AB (publ) (NASDAQ OMX), in the acquisition of the operations of TNTGamble, Inc. d/b/a Nutraceutix®, a leading U.S. manufacturer and supplier of probiotics, headquartered in Redmond, WA, with operations in Lafayette, CO.

Discovery Technologies

  • Aptar Pharma’s (part of AptarGroup. Inc.) collaboration with Propeller Health to launch a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The platform will span inhaled, injectable, nasal and dermal medicine delivery forms, and combine software and experiences with connected drug delivery devices. Aptar and Propeller will co-market the platform, with Propeller managing the digital services and Aptar managing the device development, manufacturing and supply chain.
  • BioInvent International AB’s collaboration with Transgene S.A. to co-develop next generation oncolytic virus candidates encoding a CTLA-4 antibody sequence—potentially with additional transgenes— capable to treating multiple types of solid tumors. Under the terms of the agreement, Transgene will contribute its virus design and engineering expertise and BioInvent will provide its cancer biology and antibody expertise as well as anti-CTLA-4 monoclonal antibody coding sequences.  The collaboration’s research and development costs, and revenues and royalties from candidates generated by the collaboration, will be shared 50:50.
  • Diaprost AB’s exclusive research and option agreement with a leading pharmaceutical company under which its partner will have exclusive rights to further develop a therapy against prostate cancer based on h11B6, the lead candidate in Diaprost’s kallikrein-related peptidase 2 (hK2) antibody program, with an option to acquire the asset. Under the terms of the agreement, Diaprost will receive an upfront payment, research funding and potential development milestone payments.
  • Immunova LLC’s joint venture with SalvaRx Limited focused on the use of nanolipogel technology invented at Yale University. The joint venture agreement creates a new company called Saugatuck Therapeutics Ltd which has acquired an exclusive license from Yale University through Immunova for the use of the nanolipogel platform for delivering DNA aptamers and certain aptamer-based combination products. Under the terms of the agreement, SalvaRx will initially invest $1 million to be release in tranches on the completion of milestones.  The first tranche will provide Saugatuck $300,000 to be used to establish proof of concept for the joint venture.
  • Aptar Pharma’s (part of AptarGroup, Inc.) partnership with Kali Care to develop connected ophthalmic drug delivery devices by combining Aptar’s ophthalmic device expertise and Kali Care’s proprietary digital monitoring system for ophthalmic medications in order to address the challenge of monitoring adherence in ophthalmic clinical trials.
  • Alexion Pharmaceuticals, Inc.’s license with Arbutus Biopharma Corporation to use Arbutus’ proprietary lipid nanoparticle technology for exclusive use in one of Alexion’s rare disease programs. Arbutus will conduct technology development and provide manufacturing and regulatory support for Alexion’s mRNA product candidate. Under the terms of the license agreement, Alexion will pay Arbutus $7.5 million upfront, and payments of up to $75 million for achievement of development, regulatory and commercial milestones, as well as single digit royalties.
  • Ferring Pharmaceuticals’ license and early development agreement with Enteris BioPharma, Inc. to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.  The collaboration will leverage Peptelligence™, Enteris’ proprietary peptide and small molecule oral drug delivery platform. Under the terms of the agreement, Enteris will license to Ferring its oral drug delivery technologies and provide clinical trial finished product. Ferring will pay milestones and royalties based on net sales of the developed product.
  • Ferring Pharmaceuticals’ exclusive license from Intralytix, Inc. expands a previous collaboration between the parties for the development and commercialization of bacteriophage-based therapies for inflammatory bowel disease. Under the new agreement, the parties will jointly investigate bacteriophage-based drugs to regulate the microbiome of the oral cavity, skin, and female reproductive tract.
  • BioInvent International AB’s collaboration and license agreement with Pfizer Inc. to undertake a research collaboration to discover and develop novel immuno-regulatory antibodies to treat cancer. BioInvent will apply its unbiased translational drug discovery platform (“F.I.R.S.T.”) to identify novel oncology targets and therapeutic antibodies targeting tumor-associated myeloid cells. BioInvent will receive approximately $10 million in early payments, including an upfront payment, early research funding and an equity investment.  Assuming five antibodies are developed through to commercialization, BioInvent would be eligible for potential future development milestone payments of more than $0.5 billion through the term of the deal, as well as double digit royalties on sales of products that result from the collaboration.
  • Nuevolution A/S (publ)’s collaboration and license agreement with Almirall S.A. to undertake a research collaboration to develop and commercialize novel RORyt inhibitors for treatment of inflammatory skin diseases as well as Psoriatic Arthritis. The parties will collaborate to identify additional RORyt inhibitors. Almirall has an exclusive option to use the additional inhibitors in the dermatological field and with the optional use outside the field of collaboration for Nuevolution. Nuevolution will receive €11.2 million upfront and is eligible to receive up to € 172 million in development and regulatory milestone payments and up to EUR €270 million in tiered commercial sales milestones. Nuevolution would also be entitled to receive tiered royalties on future sales.
  • Nuevolution A/S (publ)’s collaboration and license agreement with Amgen, Inc. to undertake a research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics® drug discovery platform to discover and advance potential therapeutics of interest to Amgen. Amgen has an exclusive option to obtain all rights to successfully developed programs. Nuevolution is eligible to receive up to $410 million in upfront and milestone payments per target, and would also be entitled to receive royalties on future sales.
  • Lipigon Pharmaceuticals AB’s agreement with AstraZeneca PLC to undertake a research collaboration to identify drug candidates that promote the stabilization of lipoprotein lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease. AstraZeneca is responsible for clinical development and will have worldwide marketing and commercialization rights to any resulting products. Lipigon is eligible to receive up to $110 million in development and sales milestone payments.
  • Targovax ASA’s agreement with Ludwig Cancer Research and Cancer Research Institute to evaluate Targovax’s experimental virotherapy in early-phase clinical trials in combination with other potentially synergistic immunotherapies.
  • Nuevolution A/S’s collaboration with Janssen Biotech for the discovery of compounds targeting multiple targets. Within the framework of the collaboration, Nuevolution will apply its drug discovery platform Chemetics® to discover and advance drug candidates against multiple drug targets of interest to Janssen for the treatment of oncological, infectious and inflammatory diseases.
  • BioInvent International AB's expanded collaboration with the University of Southampton and Cancer Research Technology Ltd to develop new immunotherapy treatments for cancer using antibodies targeting OX40 and 4-1BB, known as ‘co-receptors’ that help stimulate the production of killer T-cells during an immune response.
  • Santaris Pharma A/S’s agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. in which Santaris licensed its Locked Nucleic Acid (LNA) Drug Platform to discover and develop RNA-targeted medicines against a multitude of targets across several disease areas. Under the terms of the agreement, Santaris received an upfront payment of US$10 million and is eligible to receive up to US$138M in potential milestone payments per product and funding of ongoing discovery and research activities. Santaris will also be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.
  • Nuevolution A/S’s license to Novartis that expands upon a previous collaboration between the parties. Under the agreement, Nuevolution will transfer know-how to Novartis to enable Novartis to practice Nuevolution’s proprietary Chemetics® for Novartis’ own internal use. The companies will work together to co-produce novel screening libraries, and Nuevolution will receive an upfront payment, research funding and milestone payments as technology transfer progresses.
  • Santaris Pharma A/S’s agreements with RaNA Therapeutics, Inc., Isarna Therapeutics GmbH, and Miragen Therapeutics, Inc. in which Santaris licensed its Locked Nucleic Acid (LNA) Drug Platform to develop LNA-based drug candidates. Under the agreements, Santaris received an upfront payment and is eligible for target nomination payments, milestones and royalties.
  • Nuevolution A/S’s collaboration with Cancer Research Technology to identify drug leads that block the activity of certain cancer targets, and a subsequent three-way collaboration with Cancer Research Technology and The Institute of Cancer Research under which the parties will utilize Nuevolution’s proprietary Chemetics® drug discovery technology to screen libraries to identify novel lead candidates for cancer treatment. Under the three-way collaboration agreement, the parties have an option to co-develop compounds arising from the collaboration.
  • Affibody AB’s agreements with Amylin Pharmaceuticals (acquired by MedImmune/ AstraZeneca), Biotest AG, Daiichi Sankyo Company Limited, Daewoong Pharmaceutical Co., Ltd. and AbClon, Inc. for the use of Affibody’s proprietary Albumod™ platform, which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, with undisclosed molecules from the partners' pipelines of proprietary protein therapeutics. Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the platform technology.
  • Purdue Pharma L.P.’s collaboration with ElMindA Ltd. for the use of ElMindA’s Brain Networks Activation (BNA™) technology to research efforts for the development of diagnostic tools and biomarkers for pain management.

Products in Development and Approved Products

  • Affibody AB’s collaboration and license agreement with Alexion Pharmaceuticals, Inc. to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn). ABY-039 has been specifically designed to combine Affibody’s proprietary protein therapeutics platforms to achieve a long half-life, which, along with its small size provides the potential for less frequent, convenient, at-home subcutaneous administration.  Under the terms of the agreement, Affibody is eligible to receive up to $650 million in upfront payments, and development and sales milestones, and tiered low double-digit royalties. Affibody retained the rights to lead clinical development of ABY-039 in an undisclosed indication and has the option to co-promote ABY-039 in the United States.
  • Klaria AB’s exclusive development agreements with Purdue Pharma (Canada) for each of KL-00514, a naloxone buccal film intended for acute treatment of intentional or accidental opioid overdose, and KL-01401, an epinephrine oromucosal film for emergency treatment of severe anaphylactic reactions.  The co-development programs for each product will include formulation selection and optimization, pre-clinical studies and clinical trials.  The development agreements both include global license options for Purdue’s independently associated network of companies upon achievement of defined milestones. Purdue Pharma (Canada) will pay Klaria a combination of upfront, milestone, success-based payments plus a royalty on sales and possible income from Klaria’s exclusive supply of the product. Staged, success-based payments during the development phase and regulatory approval process will total around $2.3 million for KL-00514 and $55.2 million for KL-01401.
  • BioInvent International AB's manufacturing agreement with CardioVax for the production of orticumab, previously known as BI-204, following on from a global license agreement signed between BioInvent and CardioVax for the development of antibody therapeutics for treatment of inflammatory diseases.  BioInvent is expected to generate short-term manufacturing revenue of around US$3 million.
  • IsoPlexis Corporation’s exclusive agreement with Tekon Biotech to distribute IsoPlexis’s products in China, including the award-winning IsoCode and IsoLight systems that provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection.
  • Photocure ASA’s exclusive distribution agreement with Combat Medical for the Nordic region for Combat’s patented medical device designed for the delivery of Hyperthermic Intra-Vesical Chemotherapy (HIVEC®) for non-muscle invasive bladder cancer.
  • Swedish Orphan Biovitrum AB’s exclusive license and acquisition of global rights for emapalumab from Novimmune SA.  Emapalumab is a late stage orphan drug candidate that addresses a high unmet medical need in primary haemophagocytic lymphohistiocytosis, a rare and life-threatening syndrome of extreme immune activation.  Under the terms of the agreement, SOBI will make an upfront payment of 50 million Swiss francs and additional milestone payments of 400 million Swiss francs.
  • Boehringer Ingelheim’s support of a new multi-year collaborative initiative with the American Heart Association and the American Diabetes Association to raise awareness among consumers, patients and health care providers about the dangerous link between type 2 diabetes and cardiovascular disease, and to provide quality improvement measures for clinics, practices and hospitals treating patients with type 2 diabetes. Novo Nordisk and Eli Lilly and Company are also providing support for the new initiative.
  • Arysta LifeScience’s long-term commercial agreement with Isagro S.p.A. to distribute Isagro’s Fluindapyr-based mixtures for use in soybeans and other row crops in Brazil. Fluindapyr has been shown to be highly effective in controlling Asian soybean rust when used in certain formulations.
  • PledPharma AB’s license agreement with Solasia Pharma K.K. for exclusive development and commercialization in several major Asian markets of PledPharma’s product PledOx®, for prevention of chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Solasia will pay up front, development, regulatory and sales milestones of up to around US$ 83 million, and industry standard royalty rates on sales for a deal pertaining to an in-licensed asset in Phase III development. Solasia will also fully finance an expansion of the Phase III program to include Asian patients.
  • Diaprost AB’s exclusive research and option agreement with a leading pharmaceutical company under which its partner will have exclusive rights to further develop a therapy against prostate cancer based on h11B6, the lead candidate in Diaprost’s kallikrein-related peptidase 2 (hK2) antibody program, with an option to acquire the asset. Under the terms of the agreement, Diaprost will receive an upfront payment, research funding and potential development milestone payments.
  • Alligator Bioscience AB’s strategic partnership with Aptevo Therapeutics Inc. to co-develop a novel immunotherapy bispecific antibody, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016.  The new candidate was developed using Aptevo’s bispecific technology platform and includes proprietary binding elements generated by Alligator’s ALLGATOR-GOLD® antibody library. Under the terms of the agreement, the parties will jointly own and share equally in the development costs through the end of Phase 2.  At that time, the parties may opt to out-license the candidate or continue further development separately or in partnership. The agreement also provides an option for the companies to develop a second bispecific antibody candidate.
  • BioArctic AB’s agreement granting rights to AbbVie Inc. to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. BioArctic’s lead Parkinson’s antibody is BAN0805, a clinical phase antibody targeting toxic forms of the alpha-synuclein protein.
  • Medivir AB’s exclusive license to Trek Therapeutics, PBC to develop and commercialize Medivir’s MIV-802 globally, excluding China, Taiwan, Hong Kong and Macau. MIV-802 is a nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus infection.  Biophausia AB, a Medivir subsidiary, was granted options to commercialize MIV-802 containing products in the Nordics and certain Western European countries. Medivir is entitled to receive milestones based on successful clinical development and royalties capped at a mid-teens percentage upon commercialization of MIV-802 containing products.
  • Arysta Life Science’s exclusive global (excluding China) license of proprietary immunoprotein biopesticides from the Institute of Plant Protection, part of the Chinese Academy of Agricultural Science. The agreement gives Arysta LifeScience access to the protein technologies as well as all related end-use formulations and the right to develop new solo formulations and mixtures.
  • Immunova LLC’s exclusive license of its IMM-01 nanolipogel drug delivery technology to Modulate Therapeutics Inc. for delivering a TGF beta inhibitor combined with IL-2 to tumors.  Modulate Therapeutics Inc., a special purpose company based in Montréal, Québec, plans to develop, to clinical proof-of-concept, IMM-01 which is designed to re-engage the immune system in order to recognize and eradicate neoplastic disease.
  • Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Material Development Activity to explore expansion and potential development of Tonix's investigational new drug, TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment of military-related PTSD.
  • Targovax ASA’s clinical trial cooperation agreement with Sotio a.s. to conduct a collaboration study combining ONCOS-102 and Sotio's dendritic cell therapy to evaluate the safety and tolerability in the treatment of advanced prostate cancer.
  • Alligator Bioscience AB’s collaboration and license with Janssen Biotech under which Janssen is granted an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013, an agonistic fully human monoclonal antibody targeting CD40, an immuno-stimulatory receptor. Alligator receives an up-front payment plus additional contingent payments upon reaching certain pre-determined development, regulatory and commercial milestones up to a potential total of US$700 million. Alligator is also eligible to receive tiered royalties on worldwide net sales. In a simultaneous transaction a Janssen affiliate subscribed for new shares of Alligator common stock.
  • Cantargia AB’s non-exclusive license with BioWa Inc. to the POTELLIGENT® Technology platform for the production of the proprietary product candidate CAN04. The POTELLIGENT® platform has been designed for research and development of antibody dependent cellular cytotoxicity (ADCC) enhanced antibodies.
  • Photocure ASA’s agreement with Juno Pharmaceuticals as the exclusive distributor in Australia and New Zealand for the registration and commercialization of Photocure’s product Hexvix® (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis of bladder cancer.
  • Swedish Orphan Biovitrum International AB’s (Sobi) agreement and subsequent restructuring and extension with Exelixis, Inc. for exclusive distribution rights in the European Union, Switzerland, Norway, Russia and Turkey of COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
  • Nuevolution A/S’s license to MSD, a subsidiary of Merck & Co, Inc., for the exclusive development and commercialization of certain small molecule compounds targeting an intracellular target. Under the agreement, Nuevolution received an upfront payment and is eligible to receive development and commercial milestones. In addition, Nuevolution will also receive royalties on the commercial sales of approved products.
  • Azure Biotech, Inc.’s license agreement with Ligand Pharmaceuticals Incorporated for the development of a novel formation of lasofoxifene targeting an underserved market in women’s health.  Under the agreement, Ligand is entitled to receive US$2.7 million in potential development and regulatory milestones and a 5% royalty on future net sales.
  • Photocure ASA’s exclusive worldwide license agreement with Asieris Meditech Co., Ltd to develop and commercialize Cevira® for the treatment of HPV-induced cervical precancerous lesions.  Under the agreement, Photocure will receive a total signing fee of $5 million within six months of signing.  Photocure would also be eligible to receive up to $54 million upon Asieris’ achievement of certain clinical and regulatory milestones in China, the US and EU, and up to an additional $14 million for approval of a second indication in China, the US and the EU.  Additionally, sales milestone payments and royalties of 10 to 20% will apply in all markets.


Representative Mergers and Acquisitions Transactions

The following is a list of representative mergers, acquisitions and divestments in which Wiggin and Dana acted as lead counsel for clients in the biotechnology, pharmaceutical and medical device industries. Each transaction is described according to its status upon completion of the transaction.

  • Represented Olink Proteomics Holding AB in the sale of Olink Proteomics to Summa Equity, a Swedish-based private equity firm that focuses on investments in companies that help solve global challenges. Olink Proteomics is a life science company that has developed a unique technology for human biomarker discovery. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide.
  • Represented Medivir AB in its acquisition of two clinical stage oncology programs from Tetralogic Pharmaceuticals Corporation, including remetinostat, a skin-directed HDAC inhibitor, and birinapant, a bivalent SMAC mimetic, and all intellectual property and data associated with Tetralogic’s HDAC inhibitor and SMAC mimetics projects. Medivir will also assume agreements or certain obligations with other third parties, including an agreement with Merck & Co., Inc. (MSD outside of the US and Canada) for a phase I study of birinapant in combination with Keytruda™, subject to confirmation from Merck.  Tetralogic and other third party licensees are eligible to receive various development milestone payments and royalties.
  • Represented Cormorant Pharmaceuticals AB in its stock purchase agreement in connection with the sale to Bristol-Myers Squibb Company (BMS) of all of Cormorant’s outstanding capital stock and in which BMS obtained full rights to Cormorant's lead antibody candidate, HuMax-IL8. HuMax-IL8 is a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) that represents a complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules. Payments by BMS to the Cormorant equity holders could reach a total of $520 million if all clinical and regulatory milestones are achieved.
  • Represented Probi AB (publ) (NASDAQ OMX), in the acquisition of the operations of TNTGamble, Inc. d/b/a Nutraceutix®, a leading U.S. manufacturer and supplier of probiotics, headquartered in Redmond, WA, with operations in Lafayette, CO.
  • United States counsel to Gyros AB, a pioneer in automated nanoliter-scale immunoassays, in its merger with Protein Technologies AB, a leading provider of peptide synthesis instrumentation and reagents.
  • Negotiation and closing of the $265 million sale of SurgiQuest, Inc. by merger into a subsidiary of ConMed Corporation (NASDAQ: CNMD).
  • Represented Olink Bioscience AB in its sale to Sigma-Aldrich Corporation (NASDAQ) of the Duolink® product portfolio and related assets.
  • Represented Galecto Biotech AB in its agreement with Bristol-Myers Squibb Company (NYSE) for the exclusive option to acquire Galecto and gain worldwide rights to its lead asset, TD139, a novel inhaled inhibitor of galectin-3, a product in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions. Under the agreement, Galecto will receive up to US$444 million if BMS exercises its option and all contingent payments are made.
  • Represented Premacure Holding AB in the sale to Shire plc (LSE) of Premacure AB, a company that is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare and potentially blinding disorder that inflicts primarily premature infants. Shire purchased Premacure AB for an upfront payment and certain contingent payments based on the achievement of pre-specified development and commercial milestones.
  • Represented Orphazyme ApS’s acquisition of CytRx Corporation’s (NASDAQ) molecular chaperone assets for use in the development of therapeutics for genetic lysosomal storage diseases. CytRx is eligible to receive up to US$120 million plus royalties on sales of products developed by Orphazyme from the molecular chaperone technology.
  • Represented Meda AB (publ) (OMX) and its affiliate in their acquisition from Novartis of the global rights to manufacture, market, and commercialize skin medication Elidel® for US$420 million.
  • Represented Meda AB (publ) (OMX) in the acquisition of three over-the-counter consumer products in the United States from GlaxoSmithKline LLC for a purchase price of approximately US$35 million.
  • Represented Meda AB (publ) (OMX) in the acquisition of global rights and assets relating to MUSE (transurethral alprostadil), a product approved for the treatment of erectile dysfunction from VIVUS, Inc. (NASDAQ) for US$23.5 million, including an upfront cash payment of US$22 million and a potential sales milestone of US$1.5 million based on future sales of MUSE.
  • Represented Meda AB (publ) (OMX) in the acquisition of ALVP Holdings, LLC, the holding company of Alaven, a U.S.-based specialty pharmaceutical company with a focus in gastroenterology and women’s health products, for US$350 million.
  • Represented CGI Pharmaceuticals, Inc. in connection with its merger into a wholly-owned subsidiary of Gilead Sciences, Inc. in exchange for cash consideration of up to US$120 million.
  • Represented Photocure ASA (OSE) in the divestment of its photodynamic therapy products, Metvix® topical cream and the Aktilite® lamps, which are indicated for the treatment of basal cell carcinoma and actinic keratinosis in many countries, to Galderma S.A. for €51 million.
  • Represented Biovitrum AB (publ) (STO) in the acquisition of the marketed biologics Kepivance® (palifermin) and Stemgen® (ancestim) and the licensing of worldwide, exclusive rights to Kineret® (anakinra) for its current approved indication from Amgen Inc. (NASDAQ).